Table 4.
Treatment | SUCRA | PrRank1 | Mean Rank |
---|---|---|---|
Moderate to severe disease | |||
DPCP | 87.9 | 50.4 | 1.8 |
Laser | 77.9 | 26.9 | 2.6 |
Topical minoxidil | 55.5 | 4.8 | 4.1 |
Topical corticosteroids | 50.1 | 11.0 | 3.4 |
SADBE | 49.7 | 1.9 | 4.5 |
Topical tofacitinib | 47.6 | 5.0 | 4.7 |
Control | 16.2 | 0.00 | 6.9 |
Mild disease | |||
Intralesional corticosteroids | 78.9 | 36.2 | 2.5 |
Topical corticosteroids | 67.9 | 24.6 | 3.8 |
Prostaglandin analogs | 67.1 | 21.9 | 3.3 |
DPCP | 63.4 | 22.0 | 3.6 |
Topical minoxidil | 61.2 | 11.1 | 3.7 |
SADBE | 35.0 | 3.9 | 5.5 |
Calcineurin inhibitors | 12.3 | 0.6 | 7.1 |
Control | 21.7 | 0.00 | 6.5 |
SUCRA, surface under the cumulative ranking curve; PrRank1, probability of a treatment to ranking first.